by Avery Hurt In 1950, researchers Hector Chevigny and Sydell Braverman set out to, as they put it, “demolish old fables about the emotional life of the blind” and demonstrate that the mental health issues of the blind are no different from those experienced by the sighted. But they did discover one big — and very surprising — difference: There have been no reported cases of schizophrenia in people blind from birth (or who became blind very shortly after birth). At the time, there was limited patient data available, so it wasn’t clear if this astonishing finding would hold up. But in the almost 80 years since, more national databases of mental illness have been maintained, and still no cases have been found, according to a study in Frontiers in Psychology. Is it just a coincidence? Or does never having been able to see somehow offer protection from schizophrenia? And if it does, how would that even work? Schizophrenia is a neurodevelopmental disorder that interferes with the way people interpret reality, Philip Corlett, a neuroscientist at Yale University who studies psychosis and delusional thinking, told Discover. Schizophrenia can cause symptoms such as hallucinations, disorganized speech and thinking, and in some cases, a lack of motivation or engagement with the world. However, the most familiar characteristic of the illness is what Corlett described as “departures from consensus reality,” or, put another way, believing things that most people in your culture don’t believe. Though the causes and mechanisms of schizophrenia are not yet well understood, one increasingly accepted theory is that the illness results from errors in prediction. To understand that, we need to take a look at how the healthy brain processes information. © 2026 Discover Magazine Inc

Keyword: Schizophrenia; Attention
Link ID: 30320 - Posted: 07.11.2026

By Jeneen Interlandi In the mid-2010s, when they were still postdoctoral fellows at the Massachusetts Institute of Technology, Mathilde Poyet and Mathieu Groussin kept bumping into different sides of the same obstacle. Poyet, an ecologist and a microbiologist, was trying to study rare bacterial species, the kind that had never been grown in a lab before. Groussin, a computational biologist in the same lab, wanted to understand how humans and microbes evolved together over millenniums. Each was focused on microbes that make their homes in and on the human body, what scientists collectively refer to as the human microbiome. But the only samples they could find to work with came from the same small sliver of humanity, namely populations that were wealthy, Western and white. “About 90 percent of all human diversity has been completely left out of the picture,” Groussin told me recently. It was as if someone had shone a bright flashlight on one small segment of a giant canvas and left the rest shrouded in darkness. The bright spot was well defined (imagine the face of a man). But they couldn’t really tell what they were looking at (whether that man was a monk, for example, or a matador) without seeing the rest of the canvas. Scientists refer to this vast, unexplored terrain as biology’s dark matter. Our bodies are home to more bacteria — on our skin, up our noses, in our guts and mouths and around our genitals — than there are stars in the Milky Way. These microbes have evolved not only with us but inside us, and scientists who study them closely say that hardly a biological process or system exists in which they do not play a role. They helped create our digestive systems and our immune systems. They influence the size and shape of our bodies. At least some research suggests that they also affect our brains, moods, personalities and behaviors. And yet, most of them have still not been identified, let alone studied. It was tantalizing to think about what a fuller picture might reveal. In recent years, scientists had linked the gut microbiome to a long list of conditions, including Crohn’s and irritable bowel syndrome, Parkinson’s, dementia and autism, and they were hopeful that a better understanding of those links would lead to treatments, if not cures. They were also sifting through the nearly unfathomable array of molecules that microbes produce, in search of biological treasures: not only potential medications but also compounds capable of breaking down pollutants or repairing damaged ecosystems. © 2026 The New York Times Company

Keyword: Obesity
Link ID: 30312 - Posted: 07.08.2026

Hannah Harris Green A range of other medications could serve as alternatives to powerful opioids for pain relief in emergency departments, according to a new study. The review paper examined non-opioid medications available in the emergency department at San Francisco general hospital and examined existing medical literature to figure out which ones might provide pain relief. Opioids have a strong track record of reducing pain effectively, but loose prescriptions with insufficient care towards their addictive properties led to the first wave of the US opioid crisis, which began in the 90s. Akash Shanmugam, a medical student at the University of California, San Francisco (UCSF) and first author on the study, said the goal of the study was to “create a very targeted list for specific pain conditions”, to help add to the “toolboxes” physicians use to treat patients. The study provides recommendations for the most common types of pain that patients experience in emergency departments; abdominal pain, back pain, chest pain, fracture pain and headache. Shanmugam and Dr Kathy LeSaint, an associate professor of emergency medicine at UCSF and another of the paper’s authors, agree that opioids still have a place in medicine. “The desire to reduce opioids shouldn’t come at the expense of under-treating pain,” Shanmugam said. However, alternatives can also have an important role as physicians have become increasingly aware of possible long-term consequences. LeSaint also pointed out that beyond concerns about opioid addiction and overdose, it’s important to have a variety of medications for pain available because what will work best varies from person to person. This variation is often genetic; for example “the enzymes that are responsible for metabolizing opioids can have different strengths in people”, LeSaint explained. © 2026 Guardian News & Media Limited

Keyword: Pain & Touch; Drug Abuse
Link ID: 30283 - Posted: 06.17.2026

Sarah Hendrickx Being autistic can be a lot of fun. I say that as an adult-diagnosed autistic (and ADHD) adult who has spent the past 20 years working in the autism world, meeting thousands of autistic people and their families, writing books, and speaking publicly on the subject. It’s not always fun, that’s for sure, but given that the nature of being human comes with a whole plethora of complexities and contradictions, light and dark, it is, of course, highly possible that a package of atypical cognitive processes, perceptions and behaviours clinically categorised as dysfunctional and disabling can also bring a whole load of satisfaction and pleasure. Even so, I imagine that, for some people, the concept of being autistic as being joyful is a tough one to square, given that the diagnostic criteria for autism spectrum disorder defines it as ‘characterised by varying but often marked and persistent deficits in social communication and social interaction’. Still not convinced? Let’s think of being autistic in the same way that we think of a socially driven person who may thrive and excel in a busy environment, and then struggle when alone, or of a highly moral person who may be jubilant when justice prevails, and then devastated when it does not – in other words, one natural tendency can bring us both challenges and elation, depending on the circumstances. The same is true for autistic characteristics. I should note that the following celebration of autistic delight does not negate or trivialise the very real and often disabling experience of living as an autistic person in a non-autistic world. I also recognise my own privilege as an autistic adult who is able to live relatively independently and with agency, but also as an autistic adult who – despite appearances – received my own diagnosis of autism by fair means, complete with the requisite impairments and deficits. © Aeon Media Group Ltd. 2012-2026.

Keyword: Autism; Intelligence
Link ID: 30274 - Posted: 06.10.2026

By Ellen Barry Most years, when thousands of psychiatrists gather for the annual meeting of the American Psychiatric Association, they walk past a scattering of protesters. There are Scientologists with megaphones; Falun Gong groups doing their exercises; and, often, former patients, saying they have been harmed by medications or electroconvulsive therapy. This year, though, the profession is facing criticism from the highest levels of the federal government. The American Psychiatric Association gathered just 10 days after Health Secretary Robert F. Kennedy Jr. announced a set of policies to encourage doctors to deprescribe, or assist patients in stopping, the most widely prescribed class of antidepressants. A current of anxiety ran through the meeting, held here this week. Many physicians in the crowd said they worried that Mr. Kennedy’s statements would prompt people to refuse medications, or to quit them and relapse. The plenary session erupted in applause when Dr. Marketa Wills, the organization’s chief executive, declared, “We will never support governmental interference in the practice of medicine.” “We are standing tall for evidence-based care,” she continued. “We are standing tall against stigma, oversimplification, and anything that would move patients further away from the care that they need.” But there were also signs that the field’s leaders are engaging, albeit cautiously, with Mr. Kennedy’s effort to curb overprescribing. Numerous sessions offered training in helping patients taper off medications. In July, the association’s president will take part in a panel convened by the Department of Health and Human Services to develop clinical guidance on tapering antidepressants. In an interview, Dr. Wills said she had been “encouraged” by the invitation to participate in the panel, and she credited the administration with “putting mental health front and center.” © 2026 The New York Times Company

Keyword: Depression
Link ID: 30256 - Posted: 05.27.2026

By Matt Richtel A 27-year-old woman began an experiment on herself early one morning in December 2024. Her laboratory was her childhood bedroom, tucked into a second-floor corner of a pale yellow house in the Boston suburbs. On a bookshelf behind her sat a small stuffed sloth and some favorite books, including “Siddhartha” by Hermann Hesse. Her parents were asleep in the room next door. Her name is Rebecca, but she goes by Becks. Sitting at her desk in a gray T-shirt, she opened a small plastic bag filled with white powder. The bag was stamped “SR-17018,” and “NOT FOR HUMAN CONSUMPTION.” She extracted some powder with a red microscooper, poured it onto a digital scale and carefully weighed out 25 milligrams. She gathered this into a blue and white pill capsule and sealed it, and then swallowed the capsule with water. It was 4:27 a.m. “It’s my turn to be a guinea pig,” Becks wrote in the online diary she was keeping of her experience. In sharing her story with The New York Times, she asked that her last name not be used so potential employers don’t discover her drug history. Becks had joined the vanguard of a dangerous, highly speculative do-it-yourself approach to getting sober. For a decade, on and off, she had been addicted to various drugs, most recently kratom, an opiate-like substance, which cleared her head and covered up her pain but required constant dosing. She feared the call of fentanyl, which she’d tried a few times. “Every morning, I woke drenched in sweat from overnight withdrawals. It was a grim existence,” she wrote of her kratom use. She tried various methods to get sober, including three short inpatient detox stays and one monthlong rehabilitation treatment. She had periods of sobriety but couldn’t sustain it. © 2026 The New York Times Company

Keyword: Drug Abuse; Depression
Link ID: 30241 - Posted: 05.09.2026

By Rachel Nuwer Despite billions of dollars spent on potential drug treatments for cocaine addiction, none have proved effective—and cocaine use is increasing in the United States and around the world. But one class of possible remedy has remained untested: psychedelics, which have shown promise for treating post-traumatic stress disorder, depression, anxiety, alcohol use disorder, smoking, and more. Now, the results of a pioneering randomized trial—more than a decade in the making—reveal a single dose of psilocybin, the psychedelic component of magic mushrooms, brought significant relief for people addicted to cocaine. The study of 40 people, described today in JAMA Network Open, showed that 180 days after treatment, 30% of the psilocybin group was completely abstaining from cocaine, versus none of the placebo group—and those who continued using the drug did so less frequently. “This is significantly better than any medication ever tested to treat cocaine use disorder,” says Stephen Ross, a professor of psychiatry at New York University who was not involved in the work. He called results “remarkable,” and the magnitude of the effects “highly substantial.” The study, funded by the University of Alabama at Birmingham (UAB) and the nonprofit Heffter Research Institute, was also notable for its participant pool. Of the 40 people who took part, more than 80% were Black and 65% earned less than $20,000 a year. “Although the study was small, one strength is that most participants had lower than average income and education, which are associated with barriers to addiction treatment,” says Nora Volkow, director of the National Institute on Drug Abuse, who was not involved in the trial. More research will be needed to replicate the findings, she says, but the study provides evidence “that psilocybin has promise for treating addiction to cocaine and potentially other illicit stimulants.” © 2026 American Association for the Advancement of Science.

Keyword: Drug Abuse
Link ID: 30240 - Posted: 05.09.2026

Ian Sample Science editor A single dose of psilocybin, the active ingredient in magic mushrooms, can induce anatomical changes in the brain, according to research among people who took the psychedelic compound for the first time. Scientists spotted apparent changes in the brain’s structure which were still apparent a month after healthy volunteers took the drug. If confirmed, they may help explain the therapeutic effects that psychedelics can have on anxiety, depression and addiction, researchers said. Evidence for the changes came from specialised scans that measured the diffusion of water along nerve bundles in the brain. They suggested that some nerve tracts had become denser and more robust after the drug was taken. While the findings are preliminary, the scientists said the opposite was seen in ageing and dementia. “It’s remarkable to see potential anatomical brain changes one month after a single dose of any drug,” said Prof Robin Carhart-Harris, a neurologist at the University of California, San Francisco, and senior author on the study. “We don’t yet know what these changes mean, but we do note that overall, people showed positive psychological changes in this study, including improved wellbeing and mental flexibility.” Scientists have long sought to understand how psychedelics affect the brain and the work has gained fresh impetus in the wake of trials and studies that suggest the compounds could be used to treat a range of mental health disorders. The drugs are thought to help by boosting flexible thinking and allowing people to escape destructive cognitive ruts. © 2026 Guardian News & Media Limited

Keyword: Depression; Brain imaging
Link ID: 30237 - Posted: 05.06.2026

By Jake Currie Psychedelics are getting a renewed boost of interest lately. The FDA recently announced they were fast-tracking research investigating psilocybin, the compound that gives magic mushrooms their magic, as a treatment for depression. Now, new research published in Nature Communications is showing just how powerful a single dose of this psychedelic compound can be. Neuropsychopharmacologists from the University of California, San Francisco recruited 28 physically and mentally healthy people who had never taken psychedelics before and gave them their inaugural magic mushroom trip. But first, they administered a single placebo dose of 1 milligram of the magic mushroom compound. Most of the subjects reported the experience was “no more unusual than an everyday state of consciousness,” which was backed up by EEG readings. After the preview, it was time for the main event. The research team fitted the participants with EEG electrodes and administered a 25-milligram dose of psilocybin. An hour into their trip, the EEGs showed a surge of entropy (or diverse neural activity), indicating they were processing more complex information. The next day all of the subjects (except one) rated the experience as the “single most unusual state of consciousness” they’d experienced in their lives (the lone holdout rated it in the top five). During the following few weeks, the newly minted psychonauts reported experiencing more insight as well as an increased sense of well-being. A full month after their first trip, they performed better on assessments of their cognitive flexibility. “Psilocybin seems to loosen up stereotyped patterns of brain activity and give people the ability to revise entrenched patterns of thought,” study author Taylor Lyons said in a statement. “The fact that these changes track with insight and improved well‑being is especially exciting.” © 2026 Nautilus

Keyword: Drug Abuse; Depression
Link ID: 30236 - Posted: 05.06.2026

By Ellen Barry As Health Secretary Robert F. Kennedy Jr. sets out to rein in the use of psychiatric medications, a group of prominent psychiatrists are developing guidance for helping patients to stop taking them, noting that providers sometimes “park” patients on medications that are no longer necessary or effective. The experts, whose first recommendations appeared in JAMA Network Open and the British Journal of Psychiatry, identify structural problems that may lead to overprescribing: There are few clinical trials showing when it is advisable to stop a medication; many providers do not regularly review whether a prescription is still needed; and psychiatry residents receive more training in starting drug prescriptions than stopping them. “We have not really taught our trainees to think about, what is the logical endpoint?” said Dr. Joseph F. Goldberg, a past president of the American Society of Clinical Psychopharmacology, which convened a group of 45 psychiatrists to agree on basic principles for “deprescribing,” as supervised drug tapering is sometimes called. “You’ll see a patient in consultation who has been parked on a medication which seems to be ineffective for years, and you’ll ask, ‘Why are you still on this medicine?’” he said. “We’ve got a bugaboo going about passive re-prescribing, and I hope we’ll see much less of that.” The new recommendations come amid rising pressure from Mr. Kennedy and his allies in the Make America Healthy Again movement, who have long made the case that Americans overuse psychiatric medications. The Department of Health and Human Services will convene expert panels on deprescribing the main class of medication used to treat depression — selective serotonin reuptake inhibitors, or S.S.R.I.s — this summer, with an eye toward developing official guidance. © 2026 The New York Times Company

Keyword: Depression
Link ID: 30228 - Posted: 05.02.2026

By Rachel E. Gross The first question Sophie Davies had was: Will it affect my memory? In the three weeks since giving birth, Ms. Davies had been in a downward spiral. She checked herself into the mother-and-baby unit of her hospital in East Anglia, England, where doctors ratcheted up the dose of Prozac she took to manage her obsessive-compulsive disorder. But every morning she woke up in tears, and every time she looked at her baby boy, she felt hollow with guilt. “I’m never going to be able to be a mom,” she recalled thinking, “or if I am, I’m not going to be able to be a good one.” A month in, a hospital worker suggested she try a headset that used an electric current to treat depression. The word “electric” gave Ms. Davies, then 34, pause. It sounded like electroconvulsive therapy, or ECT, the scary-sounding treatment that triggers seizures and can result in memory loss. This therapy was different. Transcranial direct-current stimulation, or tDCS, uses a weak electric current to shock the brain and does not produce seizures. “This is as far from ECT as a jet engine is from my bicycle,” Dr. Mark George, of the Medical University of South Carolina, where he is a leading expert in neuromodulation, a term that encompasses all therapies that use electricity to modify brain function. Ms. Davies did an internet search and confirmed that the side effects of tDCS — ringing in the ears, headaches and mild burns or irritation where the electrode pads touched the forehead — were generally transient and didn’t include amnesia. She decided to give it a try. In England, the brain stimulation device has been approved for treating depression since 2019. It can be prescribed by a doctor or purchased over the counter, where it sells for around $530. © 2026 The New York Times Company

Keyword: Depression; Brain imaging
Link ID: 30225 - Posted: 04.29.2026

By Calli McMurray Last Saturday, President Donald Trump issued an executive order outlining regulatory tweaks intended to “accelerate” U.S. research on and increase access to psychedelic drugs for mental health treatments. The measures target clinical research, not basic studies on how the drugs work. “This may not be the breakthrough the basic research community has been looking for,” says Shawn Lockery, professor of neuroscience at the University of Oregon. The order directs the U.S. Food and Drug Administration (FDA) to speed up review of psychedelic drugs and allots “at least $50 million” from the Department of Health and Human Services for state governments’ own psychedelics research programs. One section of the order, however, could eventually make it easier for basic researchers to access psychedelics for their work. The U.S. Drug Enforcement Agency (DEA) classifies most psychedelics—including psilocybin, MDMA and LSD—as Schedule I, meaning they have “no currently accepted medical use and a high potential for abuse.” Trump’s order calls for the U.S. attorney general to review “any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder” and consider it for rescheduling to the less restrictive Schedule III. To study a Schedule I drug, researchers must apply for a license and, if approved, follow strict storage and security requirements. Approval can take up to a year, says Alex Kwan, professor of biomedical engineering at Cornell University, who studies psilocybin’s mechanism of action in the brain. “It’s a decent bar to get it. It’s not easy.” © 2026 Simons Foundation

Keyword: Drug Abuse; Depression
Link ID: 30217 - Posted: 04.26.2026

By Ellen Barry Edna Foa, an Israeli American psychologist who pressed her field — and her patients — to more directly confront fear and anxiety, revolutionizing the treatment of post-traumatic stress disorder, died on March 24 at a hospital in Philadelphia. She was 88. Her death, from complications of pneumonia, was confirmed by her daughter Yael Foa. Dr. Foa completed her training in the late 1960s, when clinicians tended to treat people with severe anxiety disorders cautiously and gradually. One of her first patients, a woman with an intense fear of objects related to death, had been prescribed a course of “systematic desensitization.” Dr. Foa was instructed to visit her every day carrying a small stone from a cemetery, bringing the stone a little closer each time until at long last the patient would be able to hold it. “We started to feel that she will never get better at that rate,” Dr. Foa recalled in a 2018 podcast interview. Dr. Foa decided to move faster, driving the patient to a funeral home and bringing her inside so that the woman was forced to deal with her distress. Avoiding those feelings, Dr. Foa posited, was actually holding the patient back. This theory culminated, about a decade later, in Dr. Foa’s landmark innovation. In the 1980s, she developed prolonged exposure therapy, a structured protocol of eight to 12 90-minute sessions in which the patient recounts a traumatic event in the present tense, lingering on the most vivid and upsetting elements. Then the patient undertakes real life exposure to reminders of the event. These sessions could be uncomfortable, Dr. Foa acknowledged. But they served to ease the patient’s sensitivity and correct flawed thinking, demonstrating that there was no harm in confronting the feared object, place or event. Over the years that followed, a series of studies supported the approach’s effectiveness. © 2026 The New York Times Company

Keyword: Stress
Link ID: 30203 - Posted: 04.18.2026

By Michael S. Rosenwald Thomas S. Langner, a sociologist who helped lead a landmark study of New Yorkers that revealed striking insights about the social, cultural and economic forces that shape mental illness, died on March 16 at his home in Sandy Hook, Conn. He was 102. His wife, Susan Kassirer, confirmed the death. When “Mental Health in the Metropolis: The Midtown Manhattan Study” was published in 1962, headline writers had a field day with the top-line finding: that only 18.5 percent of Manhattan residents could be considered psychologically well adjusted, while 23 percent showed significant impairment in daily functioning. “City Gets Mental Test, Results Are Real Crazy,” Newsday declared. The Daytona Beach Morning Journal wondered: “New York Living for ‘Nuts’ Only?” The actual substance of the two-part study — the second installment appeared in 1963 — was the challenge it posed to the widely held view in psychiatry that biological and individual factors are the primary drivers of mental illness. Professor Langner, along with a team of psychiatrists, anthropologists and social workers at Cornell University Medical College (now Weill Cornell Medicine), spent more than a decade studying 1,660 people who lived on the East Side of Manhattan, between 59th and 96th Streets. The researchers concluded that developing mental illness didn’t simply come down to a genetic lottery. © 2026 The New York Times Company

Keyword: Stress; Schizophrenia
Link ID: 30198 - Posted: 04.15.2026

By Ellen Barry When Cohen Miles-Rath walks into his father’s house, the history of his psychosis is right there in front of him. There is the place where he was standing when he received a cryptic message on his phone: The devil had entered his father’s body. There is the drawer where he spotted a knife whose handle was white — the color of God! There is the floor where, as they grappled over the knife, Cohen bit off part of his father’s earlobe, and blood spattered over both of them. There is the spot where, pinned to the floor, Cohen reached up with the knife and slashed wildly at his father’s throat. The violence lasted seconds but changed his whole life. With voices still racketing in his head, Cohen found himself in jail, facing charges of second-degree assault and criminal mischief, felonies punishable by up to 10 years in prison. Stunned and bleeding, his father had pressed charges, and taken out a restraining order against him. But Cohen hadn’t killed him. In the years that followed, he had the feeling that he had walked right up to the edge of a chasm. About 300 times a year in the United States, a child kills a parent, making up around 2 percent of all homicides. A large portion of these cases involve people like Cohen: young men with severe mental illness who are living at home. When mounting symptoms of psychosis make school or work impossible, parents are the support system of last resort. Paranoid delusions can cruelly invert that logic, turning people against the figure closest to them. © 2026 The New York Times Company

Keyword: Schizophrenia; Aggression
Link ID: 30186 - Posted: 04.01.2026

By Trip Gabriel Dr. Judith L. Rapoport, a child psychiatrist who brought public awareness to obsessive-compulsive disorder with her best-selling 1989 book, “The Boy Who Couldn’t Stop Washing,” based on her groundbreaking research into the condition’s causes and treatment, died on March 7 in Washington, D.C. She was 92. Her death, at a retirement home, was from lung cancer, her husband, Stanley Rapoport, said. Dr. Rapoport’s book about obsessive-compulsive disorder, written in an engaging style for nonscientific readers, clarified that the condition was far more common than generally thought, affecting some 1 to 3 percent of the population. The disorder had long remained in the shadows because of the shame that surrounded its symptoms, which could include habits like checking and rechecking that appliances were off, performing counting rituals before doing something as simple as walking through a doorway, or scrubbing hands with soap and water until the skin was raw — any of which, uncontrollably repeated, might waste hours of the day. Dr. Rapoport showed that there was a neurological basis for obsessions, or intrusive repetitive thoughts, and also for their linked compulsions, or pointless rituals of behavior. Along with other researchers in the 1980s, she upended the received psychiatric wisdom that the disorder could be traced to emotional traumas like overly strict toilet training. Dr. Rapoport showed that obsessive-compulsive disorder is not a neurosis, but a neurological disease. She demonstrated that it ran in families, suggesting a biological origin, and she oversaw double-blind drug trials that in 1989 led the Food and Drug Administration to approve the first medication to treat the disorder, Anafranil. “People would stop her on the street and say how much she helped them,” Dr. Francisco X. Castellanos, a child psychiatrist who worked under her, said in an interview. “Her book alerted people that they could get help, that it was not their fault. It was a gigantic leap in science and also in public health.” © 2026 The New York Times Company

Keyword: OCD - Obsessive Compulsive Disorder
Link ID: 30183 - Posted: 04.01.2026

By Andrew Jacobs Over the past two years, Australia, a country long known for its strict drug laws, has been allowing psychiatrists to treat post-traumatic stress disorder with MDMA, the chemical compound better known as Ecstasy or molly. The early results have been striking, researchers say, with more than half of patients who received MDMA along with psychotherapy reporting significant relief from PTSD. Just as notably, Australian drug regulators have not recorded any serious adverse events among the nearly 200 patients who have been through the program, which includes up to three dosing sessions with MDMA, a synthetic stimulant that promotes empathy, emotional connection and feelings of euphoria. That data point is especially relevant given the contentious debate in the United States over the safety of MDMA — one that in 2024 helped sink the prospects for MDMA therapy at the Food and Drug Administration. “Compared to conventional treatments, the outcomes we’re seeing to date with MDMA-assisted therapy have been extraordinary,” said Dr. Ranil Gunewardene, a psychiatrist in Sydney who has treated more than 40 patients since the Australian regulators created a legal pathway for the drug. But Australia’s experiment with psychedelic medicine also highlights the limitations and constraints that the nascent field is likely to face as it gains wider attention from regulators and practitioners. Because Australia is the first country to legalize and regulate MDMA therapy, researchers have been especially eager for real-world data about a drug that has been pejoratively associated with rave culture. © 2026 The New York Times Company

Keyword: Stress; Drug Abuse
Link ID: 30177 - Posted: 03.25.2026

By Christina Caron On the latest season of the HBO Max hospital drama “The Pitt,” a law student named Jackson arrived in the emergency room in a state of psychosis after he “flipped out in the library” and threw a chair at a campus security guard. The news that he might have a mental illness comes as a shock to Jackson’s family, but it soon becomes clear that his break with reality didn’t come out of nowhere. Jackson has been hearing voices for months, viewers learn: “They don’t want me to pass the bar,” he says. “That’s what they told me.” It’s often assumed that psychosis symptoms such as auditory hallucinations and paranoid delusions appear out of the blue. But in reality, most patients with a first episode of psychosis have experienced milder symptoms for months or even years. What’s important, experts say, is recognizing and addressing those symptoms early. “I always tell people if I broke my leg today and got it treated today, it would heal much better than if I waited 18 months,” said Nicholas J. K. Breitborde, director of the Early Psychosis Intervention Center at the Ohio State University Wexner Medical Center. Psychosis is a disruption of the mind’s thoughts and perceptions that causes someone to lose contact with reality. People with psychosis might hear voices, as Jackson did, or see things that other people don’t. They may also have difficulty thinking clearly and may harbor false beliefs, for example the idea that other people are trying to hurt them. Other symptoms include incoherent speech and inappropriate behavior © 2026 The New York Times Company

Keyword: Schizophrenia
Link ID: 30148 - Posted: 03.07.2026

Ian Sample Science editor People with major depressive disorder can see a rapid and lasting improvement after a single dose of the psychedelic drug dimethyltryptamine (DMT) when it is combined with psychotherapy, doctors have said. A small clinical trial involving 34 people found that psychedelic-assisted therapy prompted a swift reduction in depressive symptoms that endured long after the drug had worn off, with some still feeling the benefits six months later. “There is an immediate antidepressant effect that is significantly sustained over a three-month period and that’s exciting because this is one session with a drug, embedded in psychological support,” said Dr David Erritzoe, a psychiatrist at Imperial College London and lead investigator on the trial. Although preliminary, the results add to a growing body of evidence that psychedelic drugs, when coupled with psychotherapy, could help to alleviate depression in the millions of people worldwide who do not respond to existing antidepressants or therapies. An estimated 100 million people worldwide have treatment-resistant depression, defined as a major depressive disorder that has not responded to at least two antidepressants. About half are unable to perform routine daily tasks. The trial, reported in Nature Medicine, focused on people with moderate to severe treatment-resistant depression. One half received a single 21.5mg dose of DMT infused into a vein over 10 minutes. The other half received a placebo infused the same way. All of the participants had psychotherapy and follow-up assessments. © 2026 Guardian News & Media Limited

Keyword: Depression; Drug Abuse
Link ID: 30126 - Posted: 02.18.2026

By Molly Glick Not long after upending federal diet guidelines in order to prioritize “real food” on our plates, United States Health and Human Services Secretary Robert F. Kennedy Jr. has offered a new piece of questionable advice. During a tour to promote these dietary recommendations, Kennedy recently claimed that a keto diet can cure schizophrenia—an assertion that experts have quickly thrown cold water on. The ketogenic diet promotes fat-rich meals and low amounts of carbohydrates. While keto eating has skyrocketed in popularity in recent years—it ranked the most Googled diet in the U.S. in 2020—it was initially designed in the early 20th century for patients with epilepsy. More recent studies have confirmed that the diet is effective for certain types of epilepsy because it can control seizures. Meanwhile, we have much less evidence for its impacts on symptoms of schizophrenia. So far, small studies have offered some early evidence that ketogenic diets may help people with the condition. “There is currently no credible evidence that ketogenic diets cure schizophrenia,” Mark Olfson, a psychiatrist at Columbia University, told The New York Times. Kennedy also proclaimed that the diet can essentially cure bipolar disorder, according to studies he recently read. But as with schizophrenia, keto’s impacts on bipolar disorder have only been examined in limited numbers of patients so far. Preliminary findings have also hinted that a keto diet could ease symptoms of depression. It may offer “small antidepressant benefits” for people who don’t respond to medication, according to a recently published JAMA Psychiatry paper. But this work is in the early stages as well and remains far from conclusive. © 2026 NautilusNext Inc.

Keyword: Schizophrenia; Depression
Link ID: 30109 - Posted: 02.07.2026